THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported its determination to prepay the 10% Convertible Promissory Notes issued in April and May of 2009, which were originally issued as part of a bridge financing. Opexa is delivering notice of this determination to the holders of the Notes, which is expected to result in a conversion to equity on the terms originally contemplated by the Notes, including at a conversion price of $0.50 per share.
